

10/766480

FILE 'REGISTRY' ENTERED AT 08:11:58 ON 22 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8
DICTIONARY FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1 1669 NMVPFPR|ASAFQIGISTHWYDGVGNS/SQSP

FILE 'CAPLUS' ENTERED AT 08:12:24 ON 22 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Jul 2005 VOL 143 ISS 5
FILE LAST UPDATED: 21 Jul 2005 (20050721/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

Searcher : Shears 571-272-2528

substance identification.

L2 303 S L1

L3 9 SEA FILE=CAPLUS ABB=ON PLU=ON L2 AND ((NUTRITION? OR DIET?)(S)SUPPLEMENT? OR FOOD? OR FEED?)

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 14 Jul 2005

ACCESSION NUMBER: 2005:604480 CAPLUS

Correction of: 2005:316324

DOCUMENT NUMBER: 143:76247

Correction of: 142:371954

TITLE: Gene expression profiles and microarrays for use in diagnosis and drug screening for lung cancer

INVENTOR(S): Taylor, Ian; Pauloski, Nicole R.; Bigwood, Douglas

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032495	A2	20050414	WO 2004-US34163	20041001
WO 2005032495	C1	20050616		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-508355P P 20031003

AB The present invention relates to gene expression profiles for lung cancer, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. RNA from 10 human lung tumors and from normal adjacent tissue was analyzed using Affymetrix GeneChip hybridization and 200 tumor marker genes for lung cancer are identified. The invention also provides methods and compns. for diagnostic assays for detecting cancer and therapeutic methods and compns. for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer.

IT 855561-06-7

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profiles and microarrays for use in diagnosis and drug screening for lung cancer)

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 11 Mar 2005

ACCESSION NUMBER: 2005:216606 CAPLUS

DOCUMENT NUMBER: 142:292452

TITLE: Compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on differential gene or protein expression

INVENTOR(S): Pasricha, Pankaj; Shenoy, Mohan; Winston, John

PATENT ASSIGNEE(S): Cytokine Pharmasciences, Inc., USA

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020902	A2	20050310	WO 2004-US27356	20040823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005130189	A1	20050616	US 2004-923035	20040823
PRIORITY APPLN. INFO.:			US 2003-496716P	P 20030821

AB Compns. and methods for diagnosing and treating chronic visceral hypersensitivity (CVH) and CVH-associated disorders, such as irritable bowel syndrome, are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the transcribed polynucleotides and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. The examples discuss the effects of acetic acid sensitization and CN1493 treatment on the colon and S1 dorsal root ganglia in a rat model of visceral hypersensitivity. Gene expression profiles associated with these treatments are presented, and rat CVH-related genes and polypeptides are identified.

IT 847721-13-5, β -Tubulin (human)

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 04 Mar 2005

ACCESSION NUMBER: 2005:182700 CAPLUS

DOCUMENT NUMBER: 142:238661
 TITLE: Gene expression profile in activated CD4-positive T cells useful for the diagnosis and treatment of immune-related diseases
 INVENTOR(S): Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019258	A2	20050303	WO 2004-US25788	20040810
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2005019258	A2	20050303	WO 2004-XA25788	20040810
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2003-493546P	P 20030811
			WO 2004-US25788	A 20040810

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 845221-36-5 845222-98-2 845224-38-6

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(amino acid sequence; gene expression profile in activated CD4-pos. T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 24 Feb 2005

ACCESSION NUMBER: 2005:158694 CAPLUS

DOCUMENT NUMBER: 142:238660

TITLE: Gene expression profile in activated CD4-positive T cells useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Abbas, Alexander; Clark, Hilary; Ouyang, Wenjun; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016962	A2	20050224	WO 2004-US26249	20040811
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2005016962	A2	20050224	WO 2004-XA26249	20040811
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-493546P P 20030811

WO 2004-US26249 A 20040811

AB The present invention relates to composition containing novel proteins and method of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4-pos. T-cells activated with an anti-CD23 and anti-CD28 antibodies together with

specific cytokines provides 3232 genes that are differentially expressed in comparison to resting CD4-pos. T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 845186-43-8 845188-05-8 845189-45-9

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profile in activated CD4-pos. T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 10 Jun 2004

ACCESSION NUMBER: 2004:467689 CAPLUS

DOCUMENT NUMBER: 141:37604

TITLE: Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Clark, Hilary; Hunte, Bridsell; Jackman, Janet; Schoenfeld, Jill; Williams, Mickey P.; Wood, William I.; Wu, Thomas D.; Bodary, Sarah

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 8598 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047728	A2	20040610	WO 2003-US35971	20031124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004047728	A2	20040610	WO 2003-XA35971	20031124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-429069P	P 20021126

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4+ T-cells activated with an anti-CD3 antibody together with either ICAM-1 or anti-CD28 antibody provides genes that are differentially expressed in comparison to resting CD4+ T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 701312-15-4P 701987-88-4P 701988-13-8P
702715-26-2P 702718-15-8P 702718-46-5P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 27 May 2004

ACCESSION NUMBER: 2004:430695 CAPLUS

DOCUMENT NUMBER: 141:22225

TITLE: Gene expression profiles for activated natural killer cells and their use for diagnosis and treatment of natural killer cell-related diseases

INVENTOR(S): Fong, Sherman; Dennis, Kathryn; Clark, Hilary; Chiu, Henry; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 1731 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043361	A2	20040527	WO 2003-US35268	20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2002-425235P

P 20021108

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of

immune-related diseases. Thus, specific cDNA sequences (and their encoded protein sequences) are identified which are differentially expressed in activated natural killer cells as compared to normal resting NK cells using hybridization to Affimax microarray chips and proprietary Genentech microarrays. Activation of NK cells with interleukin-12, interleukin-15, or JAM2 was monitored by FACS for cell surface expression of CD56 and CD69.

IT 696667-25-1P 696671-14-4P 696671-21-3P
696672-44-3P 696673-43-5P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; gene expression profiles for activated natural killer cells and their use for diagnosis and treatment of natural killer cell-related diseases)

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 21 May 2004

ACCESSION NUMBER: 2004:412755 CAPLUS

DOCUMENT NUMBER: 141:5810

TITLE: Differentially expressed genes and encoded proteins in differentiated macrophages that are useful for diagnosis and treatment of immune-related diseases

INVENTOR(S): Clark, Hilary; Schoenfeld, Jill; Van Lookeren, Menno; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 2940 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041170	A2	20040521	WO 2003-US34312	20031030
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.:

US 2002-423394P

P 20021101

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Specific cDNA sequences are provided which are differentially expressed (up-regulated) in differentiated macrophages at day 7 as compared to normal undifferentiated monocytes at day 0 and day 1. The encoded proteins are useful not only as

diagnostic markers for the presence of one or more immune disorders, but also serve as therapeutic targets for the treatment of those immune disorders and inflammatory immune responses..

IT 694539-54-3 694543-35-6 694548-37-3
694548-48-6 694548-90-8 694551-10-5
694552-91-5

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; differentially expressed genes and encoded proteins in differentiated macrophages that are useful for diagnosis and treatment of immune-related diseases)

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 14 May 2004

ACCESSION NUMBER: 2004:392574 CAPLUS

DOCUMENT NUMBER: 140:405466

TITLE: Differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Aggarwal, Sudeepta; Clark, Hilary; Gurney, Austin L.; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 3009 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039956	A2	20040513	WO 2003-US34381	20031028
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2002-422472P

P 20021029

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Various polypeptides of the present invention are significantly differentially expressed in isolated CD45RO cells activated by anti-CD3/anti-CD28 as compared to isolated resting CD45RO cells, isolated resting CD45RA cell, and isolated CD45RA cells activated by anti-CD3/anti-CD28 antibodies.

IT 688816-39-9 688820-97-5 688821-07-0
688822-60-8

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(amino acid sequence; differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases)

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 05 Sep 2003
 ACCESSION NUMBER: 2003:696678 CAPLUS
 DOCUMENT NUMBER: 139:212906
 TITLE: Human genes up-regulated by stimulation with ICAM-1 and/or anti-CD28 and their use in treatment of immune-related diseases
 INVENTOR(S): Bodary, Sarah C.; Clark, Hilary; Hunte, Brisdell; Jackman, Janet K.; Schoenfeld, Jill R.; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCT Int. Appl., 918 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072035	A2	20030904	WO 2003-US5241	20030221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2476518	AA	20030904	CA 2003-2476518	20030221
US 2004258678	A1	20041223	US 2003-370715	20030221
PRIORITY APPLN. INFO.:			US 2002-359461P	P 20020222
			WO 2003-US5241	W 20030221

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune related diseases. Isolated CD4+ T cells are activated with an anti-CD3 antibody (used at a concentration that does not stimulate proliferation) together with either ICAM-1, anti-CD28 antibody, or a combination of both ICAM-1 and anti-CD28. At 24 or 72 h the cells were harvested, RNA extracted, and anal. run on Affimax U95A chips. Three hundred seventy-one genes were identified whose expression was up-regulated at either of the two timepoints in activated vs. resting cells. These cDNA sequences and their encoded proteins may be useful in targeting inflammatory processes which are associated with ICAM-1 and/or anti-CD28 antibodies.

IT 588739-86-0, Protein PRO66269 (human clone DNA287199)
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

10/766480

(amino acid sequence; human genes up-regulated by stimulation with ICAM-1 and/or anti-CD28 and their use in treatment of immune-related diseases)

E50 THROUGH E80 ASSIGNED

FILE 'REGISTRY' ENTERED AT 08:15:34 ON 22 JUL 2005

L4 31 SEA FILE=REGISTRY ABB=ON PLU=ON (588739-86-0/BI OR
688816-39-9/BI OR 688820-97-5/BI OR 688821-07-0/BI OR
688822-60-8/BI OR 694539-54-3/BI OR 694543-35-6/BI OR
694548-37-3/BI OR 694548-48-6/BI OR 694548-90-8/BI OR
694551-10-5/BI OR 694552-91-5/BI OR 696667-25-1/BI OR
696671-14-4/BI OR 696671-21-3/BI OR 696672-44-3/BI OR
696673-43-5/BI OR 701312-15-4/BI OR 701987-88-4/BI OR
701988-13-8/BI OR 702715-26-2/BI OR 702718-15-8/BI OR
702718-46-5/BI OR 845186-43-8/BI OR 845188-05-8/BI OR
845189-45-9/BI OR 845221-36-5/BI OR 845222-98-2/BI OR
845224-38-6/BI OR 847721-13-5/BI OR 855561-06-7/BI)

L5 31 L1 AND L4

L5 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 855561-06-7 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNNM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 143:76247

L5 ANSWER 2 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 847721-13-5 REGISTRY
CN β -Tubulin (human) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 86: PN: WO2005020902 SEQID: 63 claimed protein
CI MAN
SQL 451

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DSPGNYVGDS DLQLERISVY
51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKECENCDC L QGFQLTHSLG GGTGSGMGTL
151 LISKVREEYP DRIMNTFSV PPKVSDTVV EPYNATLSIH IQLVENTDET
201 YCIDNEALYD ICFRTLKLAT PTYGDLNHLV SATMSGVTTS LRFPGQLNAD
251 LRKLAVNMVP FPRLBFFMPG FAPLTARSGQ QYRALTVPEL TQQMFDKNNM
===== ==
301 MAACDPRHGR YLTVATVFRG RMSMKEVDEQ MLAIQSKNSS YFVEWIPNNV

Searcher : Shears 571-272-2528

10/766480

351 KVAVCDIPPR GLKMSSTFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT
401 GEGMDEMEFT EAESNMNDLV SEYQQYQDAT AEEGEMYED DEESEAQGP
451 K
HITS AT: 257-263

REFERENCE 1: 142:292452

L5 ANSWER 3 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 845224-38-6 REGISTRY
CN Immune disease-associated protein PRO84514 (human) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 2502: PN: WO2005019258 SEQID: 2796 claimed protein
CI MAN
SQL 450

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKECENCDCCL QGFQLTHSLG GGTGSGMGTL
151 LISKVREEYP DRIMNTFSV PPKVSDTVV EPYNATLSIH QLVENTDETY
201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTS L RFPGLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EESEAQGPK

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238661

L5 ANSWER 4 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 845222-98-2 REGISTRY
CN Immune disease-associated protein PRO10347 (human) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 2186: PN: WO2005019258 SEQID: 2426 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDCCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTC L RFPGLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNMM
===== ==
301 AACDPRHGRY LTVA AVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238661

L5 ANSWER 5 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 845221-36-5 REGISTRY

Searcher : Shears 571-272-2528

10/766480

CN Immune disease-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1726: PN: WO2005019258 SEQID: 1884 claimed protein

CI MAN

SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238661

L5 ANSWER 6 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 845189-45-9 REGISTRY

CN Immune disease-associated protein PRO84514 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2502: PN: WO2005016962 SEQID: 2796 claimed protein

CI MAN

SQL 450

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
51 YNEASSHKYV PRAILVDLEP GTMDSVRS GA FGHLFRPDNF IFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKECENCDCCL QGFQLTHSLG GGTGSGMGTL
151 LISKVREEYP DRIMNTFSV PSPKVSDTVV EPYNATLSIH QLVENTDETY
201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
251 RKLAVNMVPF PRLHFFMPGF APLTRRSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EESEEAQGPK

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238660

L5 ANSWER 7 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 845188-05-8 REGISTRY

CN Immune disease-associated protein PRO10347 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2186: PN: WO2005016962 SEQID: 2426 claimed protein

CI MAN

SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN

10/766480

101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238660

L5 ANSWER 8 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 845186-43-8 REGISTRY

CN Immune disease-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1726: PN: WO2005016962 SEQID: 1884 claimed protein

CI MAN

SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 142:238660

L5 ANSWER 9 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 702718-46-5 REGISTRY

CN T lymphocyte activation-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 723: PN: WO2004047728 SEQID: 2967 claimed protein

CI MAN

SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

HITS AT: 256-262

Searcher : Shears 571-272-2528

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 10 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 702718-15-8 REGISTRY
 CN T lymphocyte activation-associated protein PRO84514 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 681: PN: WO2004047728 SEQID: 2925 claimed protein
 CI MAN
 SQL 450

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
 51 YNEASSHKYV PRAILVDLEP GTMDSVRSQA FGHLFRPDNF IFGQSGAGNN
 101 WAKGHYTEGA ELVDSVLDVV RKECENCDCCL QGFQLTHSLG GGTGSGMGTL
 151 LISKVREEYP DRIMNTFSV PPKVSDTVV EPYNATLSIH QLVENTDETY
 201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTS L RFPGQLNADL
 251 RKLAVNMVPE PRLHFFMPGF APLTRRGSSQ YRALTVPELT QQMFDKNNMM
 =====
 301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
 351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
 401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK
 HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 11 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 702715-26-2 REGISTRY
 CN T lymphocyte activation-associated protein PRO10347 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 333: PN: WO2004047728 SEQID: 2583 claimed protein
 CI MAN
 SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
 51 YNEATGGKYV PRAILVDLEP GTMDSVRSQP FGQIFRPDNF VFGQSGAGNN
 101 WAKGHYTEGA ELVDSVLDVV RKEAESDCCL QGFQLTHSLG GGTGSGMGTL
 151 LISKIREEYP DRIMNTFSV PPKVSDTVV EPYNATLSVH QLVENTDETY
 201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTC L RFPGQLNADL
 251 RKLAVNMVPE PRLHFFMPGF APLTSRGSQ YRALTVPELT QQVFDKNNMM
 =====
 301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
 351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
 401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
 HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 12 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 701988-13-8 REGISTRY
 CN T lymphocyte activation-associated protein PRO84413 (human) (9CI) (CA INDEX NAME)

10/766480

OTHER NAMES:

CN 642: PN: WO2004047728 SEQID: 2141 claimed protein

CI MAN

SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDC L QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTCL RFPQQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 13 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 701987-88-4 REGISTRY

CN T lymphocyte activation-associated protein PRO84407 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 615: PN: WO2004047728 SEQID: 2114 claimed protein

CI MAN

SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDC L QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTV EPYNATSLVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTCL RFPQQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDSANMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFRK ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

HITS AT: 256-262

REFERENCE 1: 141:37604

L5 ANSWER 14 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 701312-15-4 REGISTRY

CN T lymphocyte activation-associated protein PRO84275 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 680: PN: WO2004047728 SEQID: 678 claimed protein

CI MAN

SQL 444

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDAVL DV RKEAESCDC L QGFQLTHSLG GGTGSGMGTL
151 LISKIREEFP DRIMNTFSV PSPKVS DTV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTCL RFPQQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM

```

===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEEAE EEVA

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:37604

L5 ANSWER 15 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 696673-43-5 REGISTRY
 CN Natural killer cell activation-associated protein PRO84514 (human)
 (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 870: PN: WO2004043361 SEQID: 871 claimed protein
 CI MAN
 SQL 450

```

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
      51 YNEASSHKYV PRAILVDLEP GTMDSVRSQA FGHLFRPDNF IFGQSGAGNN
     101 WAKGHYTEGA ELVDSVLDV RKECENCDCCL QGFQLTHSLG GGTGSGMGTL
     151 LISKVREEYP DRIMNTFSV PSPKVSDTV EPYNATLSIH QLVENTDETY
     201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTSL RFPQQLNADL
     251 RKLAVNMVFP PRLHFFMPGF APLTRRSQQ YRALTVPELT QQMFDKNMM

```

```

===== ==
301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEEMYEDD EESEEAQGP

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 16 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 696672-44-3 REGISTRY
 CN Natural killer cell activation-associated protein PRO 10347 (human)
 (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 752: PN: WO2004043361 SEQID: 751 claimed protein
 CI MAN
 SQL 444

```

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
      51 YNEATGGKYV PRAILVDLEP GTMDSVRSQP FGQIFRPDNF VFGQSGAGNN
     101 WAKGHYTEGA ELVDSVLDV RKEAESDCCL QGFQLTHSLG GGTGSGMGTL
     151 LISKIREEYP DRIMNTFSV PSPKVSDTV EPYNATLSVH QLVENTDETY
     201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTCL RFPQQLNADL
     251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNMM

```

```

===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 17 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 696671-21-3 REGISTRY
CN Natural killer cell activation-associated protein PRO84413 (human)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 617: PN: WO2004043361 SEQID: 614 claimed protein
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMV PF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKDMM
===== ==
301 AACDPRHGRY LTVA AVFRGR MSMKEVDEQM LNVQNKSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 18 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 696671-14-4 REGISTRY
CN Natural killer cell activation-associated protein PRO84407 (human)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 609: PN: WO2004043361 SEQID: 606 claimed protein
CI MAN
SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
51 YNEATGGKYV PRAVLVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMV PF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
===== ==
301 AACDPRHGRY LTVA AVFRGR MSMKEVDEQM LNVQNKSSY FVEWIPNNVK
351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:22225

L5 ANSWER 19 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 696667-25-1 REGISTRY
CN Natural killer cell activation-associated protein PRO84275 (human)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 191: PN: WO2004043361 SEQID: 189 claimed protein
CI MAN
SQL 445

```

SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
      51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
     101 WAKGHYTEGA ELVDAVLDDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
     151 LISKIREEFDP DRIMNTFSV V PPKVSDTWV VEPYNATLSV HQLVENTDET
     201 YCIDNEALYD ICFRTLKLTT PTYGDLNHLV SATMSGVTTC LRFPGQLNAD
     251 LRKLAVNMVP FPRLHFFMPG FAPLTSRGSQ QYRALTVPEL TQQMFDKNNM
          =====
     301 MAACDPRHGR YLTVAAVFRG RMSMKEVDEQ MLSVQSKNSS YFVEWIPNNV
     351 KTAVCDIPPR GLKMAATFIG NSTAIQELFK RISEQFTAMF RRKAFLHWYT
     401 GEGMDEMEFT EAESNMNDLV SEYQQYQDAT AEEGEFEEEA EEEVA

```

HITS AT: 257-263

REFERENCE 1: 141:22225

L5 ANSWER 20 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 694552-91-5 REGISTRY

CN Immune-related disease-associated protein PRO84514 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1821: PN: WO2004041170 SEQID: 1821 claimed sequence

CI MAN

SQL 450

```

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DLQLERISVY
      51 YNEASSHKYV PRAILVDLEP GTMDSVRSGA FGHLFRPDNF IFGQSGAGNN
     101 WAKGHYTEGA ELVDSVLDV RKECENCDCCL QGFQLTHSLG GGTGSGMGTL
     151 LISKVREEYP DRIMNTFSV V PPKVSDTVV EPYNATLSIH QLVENTDETY
     201 CIDNEALYDI CFRTLKLATP TYGDLNHLVS ATMSGVTTS L RFPGQLNADL
     251 RKLAVNMVPF PRLHFFMPGF APLTRRGSQQ YRALTVPELT QQMFDKNNM
          =====
     301 AACDPRHGRY LTVATVFRGR MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
     351 VAVCDIPPRG LKMSSTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
     401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD EEESEAQGPK

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 21 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 694551-10-5 REGISTRY

CN Immune-related disease-associated protein PRO10347 (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1631: PN: WO2004041170 SEQID: 1631 claimed sequence

CI MAN

SQL 444

```

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
      51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
     101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
     151 LISKIREEYP DRIMNTFSV V PPKVSDTVV EPYNATLSVH QLVENTDETY
     201 CIDNEALYDI CFRTLKLTP TYGDLNHLVS ATMSGVTTC L RFPGQLNADL
     251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNNM
          =====
     301 AACDPRHGRY LTVA AVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
     351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
     401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

```

10/766480

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 22 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 694548-90-8 REGISTRY
CN Immune-related disease-associated protein PRO83694 (human) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN 1403: PN: WO2004041170 SEQID: 1403 claimed sequence
CI MAN
SQL 446

SEQ 1 MREIVHIQAG QCGNQIGTKF WEVISDEHGI DPAGGYVGDS ALQLERINVY
51 YNESSSQKYV PRAALVDLEP GTMDSVRS GP FGQLFRPDNF IFGQTGAGNN
101 WAKGHYTEGA ELVDAVLDDV RKECEHCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEF DRIMNTFSVM PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTSL RFPGQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDARNMM
===== ==
301 AACDPRHGRY LTVATVFRGP MSMKEVDEQM LAIQSKNSSY FVEWIPNNVK
351 VAVCDIPPRG LKMASTFIGN STAIQELFKR ISEQFSAMFR RKAFLHWFTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA NDGEEAFEDE EEEIDG

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 23 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 694548-48-6 REGISTRY
CN Immune-related disease-associated protein PRO84413 (human) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN 1361: PN: WO2004041170 SEQID: 1361 claimed sequence
CI MAN
SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKDDMM
===== ==
301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 24 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 694548-37-3 REGISTRY
CN Immune-related disease-associated protein PRO84407 (human) (9CI) (CA

INDEX NAME)

OTHER NAMES:

CN 1350: PN: WO2004041170 SEQID: 1350 claimed sequence

CI MAN

SQL 445

```

SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVV PSPKVS DTVV EPYNATLSVH QLVENTDETY
       201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM
          =====
       301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 25 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 694543-35-6 REGISTRY

CN Immune-related disease-associated protein PRO81429 (human) (9CI) (CA

INDEX NAME)

OTHER NAMES:

CN 844: PN: WO2004041170 SEQID: 844 claimed sequence

CI MAN

SQL 445

```

SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGSYHGDS DLQLERINVY
        51 YNEAAGNKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDSVLDVV RKESESCDCL QGFQLTHSLG GGTGSGMGTL
       151 LISKIREEYP DRIMNTFSVM PSPKVS DTVV EPYNATLSVH QLVENTDETY
       201 SIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
       251 RKLAVNMVFP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDSKNMM
          =====
       301 AACDPRHGRY LTVAIFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
       351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
       401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA DEQGEFEEEA GEDEA

```

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 26 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN

RN 694539-54-3 REGISTRY

CN Immune-related disease-associated protein PRO84275 (human) (9CI) (CA

INDEX NAME)

OTHER NAMES:

CN 458: PN: WO2004041170 SEQID: 458 claimed sequence

CI MAN

SQL 444

```

SEQ      1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
        51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
       101 WAKGHYTEGA ELVDAVLDDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL

```

10/766480

151 LISKIREEFPP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEEE EEVA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 141:5810

L5 ANSWER 27 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 688822-60-8 REGISTRY
CN Immune response-regulated protein (human clone WO2004039956-SEQID-930)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 932: PN: WO2004039956 SEQID: 930 claimed protein

CI MAN

SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 28 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
RN 688821-07-0 REGISTRY
CN Immune response-regulated protein (human clone WO2004039956-SEQID-773)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 775: PN: WO2004039956 SEQID: 773 claimed protein

CI MAN

SQL 444

SEQ 1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
51 YNEATGGKYV PRAILVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
151 LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY
201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
251 RKLAVNMVPP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNMM

=====

301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNNSSY FVEWIPNNVK
351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA

HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 29 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 688820-97-5 REGISTRY
 CN Immune response-regulated protein (human clone WO2004039956-SEQID-763)
 (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 765: PN: WO2004039956 SEQID: 763 claimed protein
 CI MAN
 SQL 445

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
 51 YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
 101 WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
 151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
 201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
 251 RKLAVNMVPP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDKNMM
 =====
 301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQKNSSY FVEWIPNNVK
 351 TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
 401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEVA
 HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 30 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 688816-39-9 REGISTRY
 CN Immune response-regulated protein (human clone WO2004039956-SEQID-304)
 (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 304: PN: WO2004039956 SEQID: 304 claimed protein
 CI MAN
 SQL 444

SEQ 1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY
 51 YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN
 101 WAKGHYTEGA ELVDAVLDDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
 151 LISKIREEFP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
 201 CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
 251 RKLAVNMVPP PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDKNMM
 =====
 301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK
 351 TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
 401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEVA
 HITS AT: 256-262

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:405466

L5 ANSWER 31 OF 31 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 588739-86-0 REGISTRY
 CN Protein PRO66269 (human clone DNA287199) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 130: PN: WO03072035 FIGURE: 130 claimed protein

CI MAN
SQL 444

```
SEQ      1 MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLDRISVY
      51 YNEATGGKYV PRAILVDLEP GTMDSVRS GP FGQIFRPDNF VFGQSGAGNN
     101 WAKGHYTEGA ELVDSVLDV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL
     151 LISKIREEYP DRIMNTFSV PSPKVS DTVV EPYNATLSVH QLVENTDETY
     201 CIDNEALYDI CFRTLKL TTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL
     251 RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQVFDKNNMM
          =====
     301 AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSY FVEWIPNNVK
     351 TAVCDIPPRG LKMAVTFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG
     401 EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEEDFGEEA EEEA
HITS AT: 256-262
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:212906

FILE 'MEDLINE' ENTERED AT 08:16:47 ON 22 JUL 2005

FILE 'BIOSIS' ENTERED AT 08:16:47 ON 22 JUL 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 08:16:47 ON 22 JUL 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

L6 1767 S L1

```
L9      11 SEA ABB=ON PLU=ON L6 AND ((NUTRITION? OR DIET?)(S)
          SUPPLEMENT? OR FOOD OR FOODSTUFF OR FEED OR FEEDSTUFF)
L10     11 DUP REM L9 (0 DUPLICATES REMOVED)
```

L10 ANSWER 1 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN

```
ACCESSION NUMBER: 2005184405 EMBASE
TITLE: Docetaxel in the management of ovarian cancer.
AUTHOR: Blagden S.P.; Kaye S.B.
CORPORATE SOURCE: Dr. S.P. Blagden, Royal Marsden Hospital, Downs Road,
                  Sutton, Surrey SM2 5PT, United Kingdom.
                  sblagden@icr.ac.uk
SOURCE: Expert Review of Anticancer Therapy, (2005) Vol. 5, No.
        2, pp. 203-214.
        Refs: 97
        ISSN: 1473-7140 CODEN: ERATBJ
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
               016 Cancer
               030 Pharmacology
               037 Drug Literature Index
               038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050512
             Last Updated on STN: 20050512
```

AB Standard first-line treatment for Stage IC-IV ovarian cancer is
currently a platinum agent or a combination of a platinum agent with a

taxane. The use of a taxane compound in addition to single-agent platinum is increasingly preferred to platinum alone. In countries such as the UK, the taxane paclitaxel has been approved by the government for first-line use. However, it has yet to receive US Food and Drug Administration approval in the USA for use in this context. Typically, in countries such as the UK, patients with advanced ovarian cancer receive a combination of paclitaxel and carboplatin first line, both drugs given 3-weekly by intravenous infusion. Subsequent trials have demonstrated that the second-generation taxane docetaxel can be used as a substitute for paclitaxel; sharing many of its actions but with a different toxicity profile. However, docetaxel has not yet received approval for standard use. Here, the clinical development of docetaxel and its present and future place in the management of ovarian cancer is discussed. .COPYRGT. 2005 Future Drugs Ltd.

L10 ANSWER 2 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004361632 EMBASE
 TITLE: Quantification of *Fusarium graminearum* in infected wheat by species specific real-time PCR applying a TaqMan probe.
 AUTHOR: Reischer G.H.; Lemmens M.; Farnleitner A.; Adler A.; Mach R.L.
 CORPORATE SOURCE: R.L. Mach, Institute for Chemical Engineering, Gene Technology Group, Vienna Univ. Technol., G., Vienna, Austria. rmach@mail.zserv.tuwien.ac.at
 SOURCE: Journal of Microbiological Methods, (2004) Vol. 59, No. 1, pp. 141-146.
 Refs: 21
 ISSN: 0167-7012 CODEN: JMIMDQ
 PUBLISHER IDENT.: S 0167-7012(04)00154-X
 COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20040909
 Last Updated on STN: 20040909

AB A new real-time PCR based method was developed for the species-specific detection, identification and quantification of *Fusarium graminearum* in planta. It utilizes a TaqMan hybridisation probe targeting the beta-tubulin gene and a plasmid standard. The assay is highly specific giving no product with DNA of closely related species. It is very sensitive, detecting down to five gene copies per reaction, and is able to produce reliable quantitative data over a range of six orders of magnitude. .COPYRGT. 2004 Elsevier B.V. All rights reserved.

L10 ANSWER 3 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2005060957 EMBASE
 TITLE: Development of docetaxel in advanced non-small-cell lung cancer.
 AUTHOR: Belani C.P.; Eckardt J.
 CORPORATE SOURCE: C.P. Belani, Univ. of Pittsburgh Sch. of Medicine, Lung and Thoracic Cancer Program, Univ. of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. cp@upmc.edu
 SOURCE: Lung Cancer, (2004) Vol. 46, No. SUPPL. 2, pp. S3-S11.

Refs: 37
 ISSN: 0169-5002 CODEN: LUCAE5
 PUBLISHER IDENT.: S 0169-5002(04)80036-9
 COUNTRY: Ireland
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 016 Cancer
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20050218
 Last Updated on STN: 20050218

AB Docetaxel, a semisynthetic taxane initially developed for the treatment of breast cancer, has a high degree of activity in lung cancer. Although the mechanisms of action of the taxanes docetaxel and paclitaxel are identical, docetaxel has almost a twofold higher binding affinity for the target site, beta tubulin. In clinical trials, individuals previously treated with paclitaxel benefited from docetaxel. Docetaxel is the standard of care in second-line therapy of advanced non-small-cell lung cancer (NSCLC) and is effective, alone and in combination, in first-line treatment of advanced NSCLC. The standard in first-line therapy of metastatic NSCLC is a platinum doublet with one of the third-generation chemotherapy agents, docetaxel, paclitaxel, gemcitabine, or vinorelbine. Each of these doublets offers similar therapeutic benefit. In a phase-III study comparing docetaxel-cisplatin and docetaxel-carboplatin with vinorelbine-cisplatin, patients treated in the two docetaxel arms had consistently improved global QoL compared to patients treated with the vinorelbine-cisplatin doublet. This landmark study led to Food and Drug Administration (FDA) approval of cisplatin-docetaxel for the treatment of advanced NSCLC. Nonplatinum doublets such as docetaxel-gemcitabine have also demonstrated efficacy and safety. Docetaxel has undergone extensive evaluation and is the only agent approved for use in both first- and second-line therapy of advanced NSCLC. .COPYRG. 2004 Elsevier Science Ltd.

L10 ANSWER 4 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003076519 EMBASE
 TITLE: Monitoring the production of aflatoxin B(1) in wheat by measuring the concentration of nor-1 mRNA.
 AUTHOR: Mayer Z.; Farber P.; Geisen R.
 CORPORATE SOURCE: R. Geisen, Fed. Research Center for Nutrition, Institute of Hygiene and Toxicology, Haid-und-Neustr. 9, 76131 Karlsruhe, Hungary. rolf.geisen@uni-karlsruhe.de
 SOURCE: Applied and Environmental Microbiology, (1 Feb 2003) Vol. 69, No. 2, pp. 1154-1158.
 Refs: 23
 ISSN: 0099-2240 CODEN: AEMIDF
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 052 Toxicology
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20030306

Last Updated on STN: 20030306

AB A real-time reverse transcription-PCR system has been used to monitor the expression of an aflatoxin biosynthetic gene of *Aspergillus flavus* in wheat. Therefore, total RNA was isolated from infected wheat samples, reverse transcribed and subjected to real-time PCR. In parallel all samples were analyzed by high-pressure liquid chromatography for aflatoxin B(1) production. The primer-probe system of the real-time PCR was targeted against nor-1, a gene of the aflatoxin biosynthetic pathway. By application of this method the nor-1 transcription was quantified during the course of incubation. After 4 days of incubation nor-1 mRNA could be detected for the first time. The amount of nor-1 mRNA increased rapidly, and the maximum was achieved after 6 days. Then, starting very slowly, the mRNA was degraded until day 8, and this was followed by a very fast degradation, reaching nondetectable levels at days 9 and 10. First traces of aflatoxin B(1) could be detected between the 5th and 6th day of incubation. The aflatoxin concentration reached its maximum after 9 days of incubation and remained constant for the whole period of observation. To ensure that differences in the nor-1 mRNA concentration were due to different expression levels, the expression of the constitutively expressed β -tubulin gene (benA56) has also been monitored. The expression of benA56 remained constant during the whole incubation time. As a parameter for fungal growth, the number of nor-1 gene copies was determined during the course of incubation. The numbers of nor-1 gene copies increased at the beginning of the incubation and reached a plateau at day 5. They correlate well with the viable counts albeit at a higher level.

L10 ANSWER 5 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003042480 EMBASE
 TITLE: Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation.
 AUTHOR: Yusuf R.Z.; Duan Z.; Lamendola D.E.; Penson R.T.; Seiden M.V.
 CORPORATE SOURCE: M.V. Seiden, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, United States. mseiden@partners.org
 SOURCE: Current Cancer Drug Targets, (2003) Vol. 3, No. 1, pp. 1-19.
 Refs: 185
 ISSN: 1568-0096 CODEN: CCDTB
 COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20030207
 Last Updated on STN: 20030207

AB It has been approximately ten years since the Food and Drug Administration (FDA) approved paclitaxel for the treatment of platinum resistant epithelial ovarian carcinoma. Since the approval, the drug has found therapeutic applications in a variety of schedules and in a wide variety of epithelial malignancies. Its novel mechanism of action provided the hope that it would demonstrate anti-neoplastic activity in multidrug resistant tumor cells. Unfortunately, as with

other chemotherapeutic drugs, resistance is commonly seen. Laboratory investigation has defined a wide variety of resistance mechanisms including overexpression of multidrug resistance (MDR-1) gene, molecular changes in the target molecule (β -tubulin), changes in apoptotic regulatory and mitosis checkpoint proteins, and more recently changes in lipid composition and potentially the overexpression of interleukin 6 (IL-6). This review describes the in vitro molecular data that define and support the various mechanisms of resistance and critically evaluates the evidence for the participation of these mechanisms in clinically relevant paclitaxel resistance. This review also explores pharmacologic attempts to modulate paclitaxel resistance, principally through inhibition of the MDR-1 drug efflux pump. Future avenues for drug resistance research and its pharmacologic manipulation in the clinic are discussed.

L10 ANSWER 6 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2002330599 EMBASE
 TITLE: PC-SPES inhibits colon cancer growth in vitro and in vivo.
 AUTHOR: Huerta S.; Arteaga J.R.; Irwin R.W.; Ikezoe T.; Heber D.; Koeffler H.P.
 CORPORATE SOURCE: S. Huerta, UCLA Center for Human Nutrition, 12-217 Warren Hall, 900 Veteran Avenue, Los Angeles, CA 90095, United States. shuerta@pol.net
 SOURCE: Cancer Research, (15 Sep 2002) Vol. 62, No. 18, pp. 5204-5209.
 Refs: 37
 ISSN: 0008-5472 CODEN: CNREA8
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20021010
 Last Updated on STN: 20021010

AB PC-SPES is a mixture of eight herbs with antiproliferative activity in prostate cancer cell lines and antitumor effects in animal models of prostate cancer. In addition, evidence of clinical efficacy in advanced prostate cancer has been reported. PC-SPES has also been shown to have antitumor activity against several other cancer cell lines including breast and neuroepithelial cancer, melanoma, and leukemia cell lines. Because of these findings, we investigated the effects of PC-SPES in vitro in colon cancer cell lines SW480, SW620, and DLD-1 and in vivo in the Apc(min) mouse, a murine model for intestinal carcinogenesis. For the in vitro studies, colon cancer cell lines were exposed to an ethanolic extract of PC-SPES compared with a diluent control [ethanol \leq 0.3% (v/v)]. PC-SPES resulted in a marked suppression of cell proliferation in all colon cancer cells studied. PC-SPES (3 μ l/ml) caused a 95% inhibition of cell proliferation of the DLD-1 colon cancer cell line, and similar results were observed in the SW480 and SW620 colon cancer cell lines. Cell cycle analysis demonstrated a drastic (\geq 60%) accumulation of cells in the G(2)-M phase with a comitant decrease of cells in the G(0)-G(1) phase in all colon cancer cell lines studied after treatment with PC-SPES (1.5 μ l/ml for 48 h). Western blot analysis demonstrated a decrease in protein levels of β -tubulin in the SW620 cell line exposed to PC-SPES. Terminal deoxynucleotidyl

transferase-mediated nick end labeling analysis revealed an increase in apoptotic colon cancer cells incubated with PC-SPES. For the in vivo studies, female 4-5-week-old Apc(min) mice were randomized to two groups: a PC-SPES-treated group (n = 11) received 250 mg/kg/day (0.2 ml) PC-SPES via gastrointestinal gavage; and a control group (n = 10) received 0.2 ml of the vehicle solution (1.5% carboxymethylcellulose with 0.2% Tween 20) via gastrointestinal gavage. Both groups were treated five times a week for 10 weeks. After treatment, the gastrointestinal tract was dissected for polyp scoring by two observers blinded to treatment. The Apc(min) mice given PC-SPES had a 58% reduction in tumor number and a 56% decrease in tumor load. No effect on either food intake or body weight was observed in the treated versus sham groups. The present study is the first to report the potent activity of PC-SPES against colon cancer. Both cell cycle arrest and apoptosis occurred after treatment with PC-SPES. This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression.

L10 ANSWER 7 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003019447 EMBASE
 TITLE: Taxanes for advanced non-small cell lung cancer.
 AUTHOR: Ramalingam S.; Belani C.P.
 CORPORATE SOURCE: S. Ramalingam, Lung Cancer Program, Univ. of Pittsburgh Sch. of Medicine, 5150 Centre Ave., Pittsburgh, PA 15232, United States. Belanicp@msx.upmc.edu
 SOURCE: Expert Opinion on Pharmacotherapy, (1 Dec 2002) Vol. 3, No. 12, pp. 1693-1709.
 Refs: 113
 ISSN: 1465-6566 CODEN: EOPHF7
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
 016 Cancer
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20030129
 Last Updated on STN: 20030129

AB The emergence of novel chemotherapeutic agents with promising anticancer activity in non-small cell lung cancer (NSCLC) during the 1990s has led to an expanded role for chemotherapy in the management of this disease. The taxanes (paclitaxel and docetaxel) are novel microtubule stabilising agents, and have become an integral part of several commonly-used chemotherapy regimens in NSCLC. Taxanes inhibit the growth of lung cancer cell lines, exhibit synergistic interaction with other chemotherapy agents and enhance the efficacy of radiation in vitro. When used in low doses (metronomic dosing), they have important antiangiogenic properties. Several Phase II and III clinical trials have established the efficacy of the taxanes, as single agents and when used in combination with a platinum compound, in the treatment of advanced NSCLC. The use of a taxane in combination with a platinum compound has become an acceptable standard for patients with advanced or metastatic NSCLC. In addition to its efficacy in the first-line therapy of NSCLC, docetaxel is also the

FDA-approved second-line agent for recurrent or relapsed NSCLC in the US. Several ongoing trials are comparing the efficacy of combining molecularly targeted agents with taxane-based regimens for the treatment of advanced NSCLC.

L10 ANSWER 8 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1999280035 EMBASE
 TITLE: Molecular tools for identification of *Penicillium* starter cultures used in the food industry.
 AUTHOR: Dupont J.; Magnin S.; Marti A.; Brousse M.
 CORPORATE SOURCE: J. Dupont, Museum National Histoire Naturelle, Inst. Systematique CNRS FR 1541, Laboratoire Cryptogamie, 12 Rue Buffon, 75005 Paris, France. jdupont@mnhn.fr
 SOURCE: International Journal of Food Microbiology, (1999) Vol. 49, No. 3, pp. 109-118.
 Refs: 31
 ISSN: 0168-1605 CODEN: IJFMDD
 PUBLISHER IDENT.: S 0168-1605(99)00055-0
 COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 19990826
 Last Updated on STN: 19990826

AB The main goal of this work was to develop rapid and accurate molecular tools to discriminate species of white industrial *Penicillia*. We applied three different polymerase chain reaction (PCR) based techniques. Sequences of the ITS region of the rRNA gene unit and of the 5' end of the β tubulin gene yielded 1.2% and 5.8% nucleotide variability respectively, between *Penicillium camembertii* and *Penicillium nalgiovense*. Polymorphic restriction sites were found in both sequences. These may be used in diagnostic PCR-RFLP analysis to rapidly distinguish between the two *Penicillium* species. Random amplified polymorphic DNA (RAPD) markers were also useful to differentiate these two species, but no polymorphism was found at the subspecific level, which evidenced a high level of homogeneity of the isolates studied. By means of these three techniques, the real identity of industrial strains of *Penicillium chrysogenum* and *P. nalgiovense* could be demonstrated. The comparison of these isolates with type strains of the two species suggested that the former corresponds to *P. nalgiovense*. The genetic relatedness between *P. nalgiovense* and *Penicillium dipodomyis* was also confirmed. Copyright (C) 1999 Elsevier Science B.V.

L10 ANSWER 9 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1998295966 EMBASE
 TITLE: Molecular phylogenetic, morphological, and mycotoxin data support reidentification of the Quorn mycoprotein fungus as *Fusarium venenatum*.
 AUTHOR: O'Donnell K.; Cigelnik E.; Casper H.H.
 CORPORATE SOURCE: K. O'Donnell, Microbial Properties Research, Natl. Ctr. Agr. Utilization Res., USDA-ARS, Peoria, IL 61604, United States
 SOURCE: Fungal Genetics and Biology, (1998) Vol. 23, No. 1, pp. 57-67.

Refs: 31
 ISSN: 1087-1845 CODEN: FGBIFV
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 004 Microbiology
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB Molecular phylogenetic, morphological, and mycotoxin data were obtained in order to investigate the relationships and identity of the Quorn mycoprotein fungus within *Fusarium* and to examine Quorn strains and commercial Quorn food products for trichothecene mycotoxins. Phylogenetic analyses of aligned DNA sequences obtained via the polymerase chain reaction from the nuclear 28S ribosomal DNA, nuclear ribosomal internal transcribed spacer region, and β -tubulin gene exons and introns indicate that the Quorn fungus is *Fusarium venenatum*, rather than *F. graminearum* as previously reported. All of the Quorn strains examined were morphologically degenerate aconidial colonial mutants except for NRRL 25139, which produced chlamydospores in recurved terminal chains together with mostly 5-septate sporodochial conidia on doliform monophialides diagnostic of *F. venenatum*. Bootstrap and decay analyses provide strong support for a monophyletic lineage containing *F. venenatum* and several other type A trichothecene-producing species, while reference strains of *F. graminearum* were nested in a separate clade of species that produce type B trichothecenes and/or zearalenone. Analysis of mycotoxins from rice cultures inoculated with Quorn strain NRRL 25416 revealed that four type A trichothecenes are produced, but at low levels relative to strain NRRL 22198 of *F. venenatum*. No trichothecene mycotoxins, however, were detected from the analysis of three commercial Quorn products marketed for human consumption in England.

L10 ANSWER 10 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 96233362 EMBASE

DOCUMENT NUMBER: 1996233362

TITLE: Genetic analysis of the *Drosophila* β 3-tubulin gene demonstrates that the microtubule cytoskeleton in the cells of the visceral mesoderm is required for morphogenesis of the midgut endoderm.

AUTHOR: Dettman R.W.; Turner F.R.; Raff E.C.

CORPORATE SOURCE: Department of Biology, Jordan Hall, Indiana University, Bloomington, IN 47405, United States

SOURCE: Developmental Biology, (1996) Vol. 177, No. 1, pp. 117-135.

ISSN: 0012-1606 CODEN: DEBIAO

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 021 Developmental Biology and Teratology
 022 Human Genetics

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 960821

Last Updated on STN: 960821

AB We have investigated the cellular basis for lethality of mutant alleles of the *Drosophila melanogaster* β 3-tubulin gene, β Tub60D. Lethal β 3 mutations can be grouped into two classes: the most severe mutations (Class I alleles) cause death during the first larval instar, while weaker alleles (Class II) cause

death in later larval stages or in early pupal development. Since $\beta 3$ is not expressed during larval development, lethality of the Class I mutations must reflect essential functions of $\beta 3$ in embryogenesis. $\beta 3$ -tubulin is zygotically expressed during midembryogenesis in the developing mesoderm, and the major site of $\beta 3$ accumulation is in the developing muscles during myogenesis. We show that the embryonic pattern of $\beta 3$ expression, including accumulation in the developing musculature, is conserved in other *Drosophila* species. However, we found that loss of $\beta 3$ function does not cause discernible defects in either the ultrastructure or function of the larval muscle. Thus $\beta 3$ -tubulin is dispensable in its highest site of accumulation. Rather, the essential site of function of $\beta 3$ in embryos is in cells of the visceral mesoderm. Lethality of Class I alleles is caused by defects in midgut morphogenesis and failure of gut function. Although the folding pattern is irregular and the gut is smaller than normal, a complete folded gut forms in mutant larvae, and the visceral muscle functions normally to move food through the gut. However, mutant larvae cannot absorb nutrients across the gut wall. Thus loss of $\beta 3$ function in the mesoderm results in defects in the underlying endodermally derived layer of the gut. Our data provide an assay for cellular interactions between mesoderm and endodermal tissues and reveal a role for the microtubule cytoskeleton of the visceral mesodermal cells in differentiation of the endodermal cell layer of the larval gut.

L10 ANSWER 11 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 93314967 EMBASE
DOCUMENT NUMBER: 1993314967
TITLE: HgEDTA complex inhibits GTP interactions with the E-site of brain β -tubulin.
AUTHOR: Duhr E.F.; Pendergrass J.C.; Slevin J.T.; Haley B.E.
CORPORATE SOURCE: Div. Medicinal Chemistry/Pharmaceut., College of Pharmacy, University of Kentucky Med. Center, Lexington, KY 40536-0093, United States
SOURCE: Toxicology and Applied Pharmacology, (1993) Vol. 122, No. 2, pp. 273-280.
ISSN: 0041-008X CODEN: TXAPA
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry
052 Toxicology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 931205
Last Updated on STN: 931205

AB We have found that EDTA and EGTA complexes of Hg^{2+} , which conventional wisdom has assumed are biologically inert, are potentially injurious to the neuronal cytoskeleton. Tubulin, a major protein component of the neuronal cytoskeleton, is the target of multiple toxicants, including many heavy metal ions. Among the mercurials, inorganic mercuric ion (Hg^{2+}) is one of the most potent inhibitors of microtubule polymerization both in vivo and in vitro. In contrast to other heavy metals, the capacity of Hg^{2+} to inhibit microtubule polymerization or disrupt formed microtubules cannot be prevented by the addition of EDTA and EGTA, both of which bind Hg^{2+} with very high

affinity. To the contrary, the addition of these two chelating agents potentiates Hg^{2+} inhibition of tubulin polymerization. Results herein show that HgEDTA and HgEGTA inhibit tubulin polymerization by disrupting the interaction of GTP with the E-site of brain β -tubulin, an obligatory step in the polymerization of tubulin. Both HgEDTA and HgEGTA , but not free Hg^{2+} , prevented binding of $[^{32}\text{P}]\text{8N3GTP}$, a photoaffinity nucleotide analog of GTP, to the E-site and displaced bound $[^{32}\text{P}]\text{8N3GTP}$ at low micromolar concentrations. This complete inhibition of photoinsertion into the E-site occurred in a concentration- and time-dependent fashion and was specific for Hg^{2+} complexes of EDTA and EGTA, among the chelating agents tested. Given the ubiquity of Hg^{2+} in the environment and the widespread use of EDTA in **foodstuffs** and medicine, these mercury complexes may pose a potentially serious threat to human health and play a role in diseases of the neuronal cytoskeleton.

FILE 'HOME' ENTERED AT 08:42:11 ON 22 JUL 2005



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number 169567

TO: Andrew D Kosar
Art Unit: 1654
Location: rem/3C04/3C18
Serial Number: 10/766480

Friday, July 22, 2005

From: Beverly Shears
Location: Biotech-Chem Library
REM 1A54
Phone: 571-272-2528
beverly.shears@uspto.gov

Search Notes

Protein Sequence Searches – February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (uniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

STIC-Biotech/ChemLib

CRFE

159567

From: Kosar, Andrew

Sent: Saturday, July 16, 2005 12:04 PM

To: STIC-Biotech/ChemLib

Subject: sequence search 10/766,480

80341

me

Please search SEQ ID NOs: 1 and 2 in 10/766,480
 please do interference search as well.
 thank you.

Andrew D. Kosar, Ph.D.
 Patent Examiner
 Art Unit 1654
 (571)272-0913
 Office REMSEN 3C04
 Mail REMSEN 3C18

1 aa 7

2 aa 20

me

7/18/05

Date completed:

Searcher: Beverly e 2528

Terminal time: _____

Elapsed time: _____

CPU time: _____

Total time: _____

Number of Searches: _____

Number of Databases: _____

Search Site

_____ STIC

_____ CM-1

_____ Pre-S

Type of Search

_____ N.A. Sequence

_____ A.A. Sequence

_____ Structure

_____ Bibliographic

Vendors

_____ IG

_____ STN

_____ Dialog

_____ APS

_____ Geninfo

_____ SDC

_____ DARC/Questel

_____ Other ☒ CE

10/766480

=> d his ful

(FILE 'HOME' ENTERED AT 08:10:12 ON 22 JUL 2005)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 08:11:58 ON 22 JUL 2005
L1 1669 SEA ABB=ON PLU=ON NMVPFPR|ASAFQGIGSTHWVYDGVGNS/SQSP

FILE 'CAPLUS' ENTERED AT 08:12:24 ON 22 JUL 2005
L2 303 SEA ABB=ON PLU=ON L1
L3 9 SEA ABB=ON PLU=ON L2 AND ((NUTRITION? OR DIET?) (S) SUPPLEM
ENT? OR FOOD? OR FEED?)
L*** DEL 0 S L3 AND MOESSLER ?/AU
L*** DEL 0 S L2 AND MOESSLER ?/AU
L*** DEL 0 S (MOESSLER H? AND (RIEDL C? OR SCHNAIT ?))/AU
D 1-9 .BEVSTR
SEL HIT L3 1-9 RN
D QUE L3

FILE 'REGISTRY' ENTERED AT 08:15:34 ON 22 JUL 2005
L4 31 SEA ABB=ON PLU=ON (588739-86-0/BI OR 688816-39-9/BI OR
688820-97-5/BI OR 688821-07-0/BI OR 688822-60-8/BI OR
694539-54-3/BI OR 694543-35-6/BI OR 694548-37-3/BI OR
694548-48-6/BI OR 694548-90-8/BI OR 694551-10-5/BI OR
694552-91-5/BI OR 696667-25-1/BI OR 696671-14-4/BI OR
696671-21-3/BI OR 696672-44-3/BI OR 696673-43-5/BI OR
701312-15-4/BI OR 701987-88-4/BI OR 701988-13-8/BI OR
702715-26-2/BI OR 702718-15-8/BI OR 702718-46-5/BI OR
845186-43-8/BI OR 845188-05-8/BI OR 845189-45-9/BI OR
845221-36-5/BI OR 845222-98-2/BI OR 845224-38-6/BI OR
847721-13-5/BI OR 855561-06-7/BI)
D QUE
L5 31 SEA ABB=ON PLU=ON L1 AND L4
D L5 1-31 .BEVREG1

FILE 'MEDLINE, BIOSIS, EMBASE, FSTA, NUTRACEUT' ENTERED AT 08:16:09
ON 22 JUL 2005
L*** DEL 1767 S L1

FILE 'FSTA' ENTERED AT 08:16:25 ON 22 JUL 2005
L*** DEL 0 S L1

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:16:47 ON 22 JUL 2005
L6 1767 SEA ABB=ON PLU=ON L1
L7 20 SEA ABB=ON PLU=ON L6 AND ((NUTRITION? OR DIET?) (S)
SUPPLEMENT? OR FOOD? OR FEED?)
L8 20 DUP REM L7 (0 DUPLICATES REMOVED)
D 1-20 IBIB ABS

FILE 'HOME' ENTERED AT 08:17:23 ON 22 JUL 2005
D COST

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:41:30 ON 22 JUL 2005
L9 11 SEA ABB=ON PLU=ON L6 AND ((NUTRITION? OR DIET?) (S)
SUPPLEMENT? OR FOOD OR FOODSTUFF OR FEED OR FEEDSTUFF)
L10 11 DUP REM L9 (0 DUPLICATES REMOVED)
D 1-11 IBIB ABS

FILE 'HOME' ENTERED AT 08:42:11 ON 22 JUL 2005

Searcher : Shears 571-272-2528

10/766480

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 08:42:43 ON 22 JUL 2005

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8

DICTIONARY FILE UPDATES: 21 JUL 2005 HIGHEST RN 856430-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMI for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2005 VOL 143 ISS 5

FILE LAST UPDATED: 21 Jul 2005 (20050721/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE

FILE LAST UPDATED: 21 JUL 2005 (20050721/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

Searcher : Shears 571-272-2528

10/766480

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 21 July 2005 (20050721/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE

FILE COVERS 1974 TO 21 Jul 2005 (20050721/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE FSTA

FILE LAST UPDATED: 18 JUL 2005 <20050718/UP>

FILE COVERS 1969 TO DATE.

FILE NUTRACEUT

FILE LAST UPDATED: 29 JUN 2005 <20050629/UP>

FILE COVERS MAY 1996 TO DATE

FILE HOME

=>